Actinogen Medical

19/10/2026

A new Actinogen Medical manuscript has been published online in the Journal of Clinical and Translational Neuroscience (pre-print) titled:

"The role of cortisol in CNS disease – 11β-HSD1 inhibition as a potential new therapeutic strategy for Alzheimer's disease and Major Depressive Disorder."

The manuscript reviews the role of cortisol dysregulation in CNS disease and presents strong nonclinical and clinical evidence supporting inhibition of the tissue cortisol synthesis enzyme 11β-HSD1 as a promising therapeutic approach.

It highlights Actinogen's lead therapy, emestedastat (Xanamem), the only known brain-penetrant 11β-HSD1 inhibitor, which is designed to regulate excess cortisol production within the brain.

The paper also highlights the ongoing pivotal trial of emestedastat in patients with mild-to-moderate Alzheimer's disease, with topline results expected in November.

Read the manuscript here:
https://www.preprints.org/manuscript/202610.1646

18/06/2026

Actinogen Medical has received another positive milestone for its pivotal XanaMIA Alzheimer’s disease trial.

The independent Data Monitoring Committee (DMC) reviewed safety data from all 247 participants and recommended the trial continue without amendment. Oral Xanamem® 10 mg daily continues to demonstrate a promising safety profile in patients with mild to moderate Alzheimer’s disease.

This is the third positive recommendation from the DMC, with final topline results expected in November 2026.

Read the full announcement on: https://tinyurl.com/3bhxvhbw

26/05/2026

It was great to get the Actinogen Medical team, friends & family together on Sunday morning in Sydney to help raise awareness & funds for a fantastic cause!

13/05/2026

Actinogen Medical is reminding holders of two tranches of unlisted options that they will expire in September 2026. CEO Dr Steven Gourlay has exercised all his unlisted options, contributing around $91,600 and taking his total personal investment to more than $2.5 million. Optionholders are encouraged to complete the process before the deadlines on 11 and 15 September 2026.

Learn more here:

Read and interact with this announcement: ACW CEO options exercise and expiry reminder on Actinogen's investor hub

13/04/2026

A great report by Tim Boreham in Biotech Daily’s “Dr Boreham’s Crucible” 🧬, highlighting the progress of Xanamem’s Alzheimer’s disease clinical trial. The piece draws on an interview we did late last year and provides a thoughtful overview of where things currently stand.

After successfully passing the pivotal trial’s interim futility and safety analysis in January ✅, we’re now looking ahead to the next major milestone—topline results expected in November 📊.
It’s an exciting period as we continue working toward meaningful outcomes for patients ❤️ and future regulatory pathways.

🔗 Read more:

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotechnology sector.

01/04/2026

We’re pleased to share that Actinogen Medical has commenced the open-label extension of its XanaMIA Alzheimer’s trial, with the first participant treated. 🧠✨

This phase allows eligible participants to receive active Xanamem®, helping generate important long-term data.

🔗 Learn more:

Read and interact with this announcement: ACW XanaMIA Alzheimers open label trial commences on Actinogen's investor hub

26/02/2026

Actinogen Medical secures $16.8m to fund pivotal Alzheimer's trial.

We've successfully completed our capital raising (Placement and SPP), ensuring our XanaMIA trial is fully funded through its most critical catalyst: topline results in November

This funding follows a string of de-risking milestones:

- FDA alignment on a streamlined pathway to approval ✅
- Full enrolment of the 247-patient Alzheimer’s trial ✅
- Positive interim safety and futility recommendation from our independent Data Monitoring Committee✅

With the major hurdles cleared, we are now in the final countdown to topline results this November.



For more info go to: https://investors.actinogen.com.au/link/PZoJ6y

13/01/2026

Actinogen Medical CCO Andrew Udell joined a panel discussion at the Biotech Showcase 2026 in San Francisco this week on emerging biotech commercialization models. The insightful session explored how the industry is moving beyond traditional models toward smarter, more capital-efficient paths to market—focusing on value creation, risk management, and the milestones that matter most.

04/11/2025

We’re pleased to share that our CEO, Dr Steve Gourlay, and CCO, Andy Udell, are representing Actinogen Medical at this year’s BIO Europe conference in Vienna (November 3 – 5).

They’ll be connecting with biotech and pharma leaders to explore innovative partnerships and new clinical opportunities.
If you’re attending and would like to meet, send us a message — we’d love to connect!

23/10/2025

📣 Actinogen Medical Webinar – Progress Update & Q&A

Join us as Actinogen Medical, we are hosting a webinar on Tuesday, 28 October at 11am AEDT!

Hear from CEO Dr Steven Gourlay and senior leaders as they share recent progress and future milestones. Stay for a Q&A session!

✅ Register now: ://actinogenmedical.zoom.us/webinar/register/WN_L_TOuTmaR4qYvYnXrNzfDQ

📺 A recording will be available after the event on our website and YouTube.

📄 Full ASX announcement: https://investors.actinogen.com.au/link/eW3Qje

Read and interact with this announcement: Advance notice ACW progress update and Q&A webinar on Actinogen's investor hub